Literature DB >> 25903207

Refractory polymyositis undergoing remission following antitubercular therapy.

Durga Prasanna Misra1, Sukesh Edavalath1, Abhra Chandra Chowdhury1, Vikas Agarwal1.   

Abstract

Opportunistic infections pose a significant problem in patients receiving immunosuppressive therapy for autoimmune diseases. We present a case of a woman with polymyositis refractory to high-dose steroid and methotrexate, as a consequence of which she developed miliary tuberculosis. Her myositis went into remission after initiation of antitubercular therapy, in spite of bringing down the intensity of immunosuppression. This is the first reported case of myositis undergoing remission after treating intercurrent infection, and illustrates the complex relationship between autoimmune disease and host response to infection. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903207      PMCID: PMC4420809          DOI: 10.1136/bcr-2015-209291

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis.

Authors:  Antti Airio; Markku Kauppi; Hannu Kautiainen; Markku Hakala; Vuokko Kinnula
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

3.  Opportunistic infections in polymyositis and dermatomyositis.

Authors:  Isabelle Marie; Eric Hachulla; Patrick Chérin; Marie-France Hellot; Serge Herson; Hervé Levesque; Pierre-Yves Hatron
Journal:  Arthritis Rheum       Date:  2005-04-15

4.  Resistant dermatomyositis complicated by tubercular myositis and successfully treated with rituximab.

Authors:  Ramesh Jois; Nikhila Vasudevan; Pradeep Srinivasan; Ravindra Mehta
Journal:  Neurol India       Date:  2011 Mar-Apr       Impact factor: 2.117

Review 5.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

6.  Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.

Authors:  Ludovic Desvignes; Andrea J Wolf; Joel D Ernst
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

Review 7.  Challenges in the diagnosis & treatment of miliary tuberculosis.

Authors:  Surendra K Sharma; Alladi Mohan; Abhishek Sharma
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

8.  Remission of rheumatoid arthritis after acute disseminated varicella-zoster infection.

Authors:  Vikas Agarwal; Ram Singh; Sandeep Chauhan
Journal:  Clin Rheumatol       Date:  2006-01-21       Impact factor: 3.650

9.  A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Authors:  Brandon W Higgs; Wei Zhu; Chris Morehouse; Wendy I White; Philip Brohawn; Xiang Guo; Marlon Rebelatto; Chenxiong Le; Anthony Amato; David Fiorentino; Steven A Greenberg; Jorn Drappa; Laura Richman; Warren Greth; Bahija Jallal; Yihong Yao
Journal:  Ann Rheum Dis       Date:  2013-02-23       Impact factor: 19.103

10.  Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies.

Authors:  Sreeram V Ramagopalan; Raph Goldacre; Andrew Skingsley; Chris Conlon; Michael J Goldacre
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.